| Literature DB >> 33209946 |
Anne Darmon-Curti1, François Darmon2, Sophie Edouard1, Aurélie Hennebique3,4, Thomas Guimard5, Guillaume Martin-Blondel6,7, Timothée Klopfenstein8, Jean-Philippe Talarmin9, Didier Raoult1,10, Max Maurin3,4, Pierre-Edouard Fournier10,11.
Abstract
BACKGROUND: We describe the epidemiological, clinical, and prognostic aspects of 177 tularemia cases diagnosed at the National Reference Center for rickettsioses, coxiellosis, and bartonelloses between 2008 and 2017.Entities:
Keywords: France; Francisella tularensis; case series; diagnosis; tularemia
Year: 2020 PMID: 33209946 PMCID: PMC7651688 DOI: 10.1093/ofid/ofaa440
Source DB: PubMed Journal: Open Forum Infect Dis ISSN: 2328-8957 Impact factor: 3.835
Figure 1. Geographical distribution of tularemia cases.
Figure 2. Source of exposure (game include boar, deer, and doe).
Comparison of the Data in Our Series With 2 Other French Series
| Data | Maurin et al [ | Mailles et al [ | Our Series |
|---|---|---|---|
| Number of patients included | 101 | 433 | 177 |
| Mean age | 51.7 | 49 | 47.38 |
| Sex ratio | 1.2 | 1.8 | 2.28 |
| Hunters | 16 (15.8%) | 52 (12%) | 39 (21.7) |
| Incubation time (days) | 5.5 | NR | 9.28 |
| Glandular forms | 24 (23.7%) | 200 (46%) | 48 (27.1%) |
| Ulceroglandular forms | 34 (33.7%) | 113 (26%) | 61 (34.5%) |
| Pleuropulmonary forms | 10 (10%) | 42 (10%) | 32 (18%) |
| Oropharyngeal forms | 17 (16.8%) | 25 (6%) | 9 (5.0%) |
| Oculoglandular forms | 4 (4%) | 8 (2%) | 4 (2.3%) |
| Typhoidal forms | 9 (8.9%) | 45 (10%) | 14 (7.9%) |
| Hospitalization | 30 (29.7%) | 188 (43%) | 78 (53.4%) |
| Complications | NR | 20 | 60 (40.8) |
| Death | 1 | 2 | 0 |
| Confirmed cases | 94 | 130 | 89 |
| Strain isolation | 16 | 30 | 0 |
| PCR | 39 | 75 | 78 |
| Serologies (seroconversion, titer ×4) | 39 | 11 | 11 |
| Probable cases | 7 | 303 | 88 |
| Cases in common with our series | 3 | 63 |
Abbreviations: NR, not reported; PCR, polymerase chain reaction.
Clinical Data of 177 Patients in France (2008–2017): Comparison With Data From 5 Previously Reported Case Seriesa
| Data | Ref [ | Ref [ | Ref [ | Ref [ | Ref [ | Our Study |
|---|---|---|---|---|---|---|
| Country | USA | Sweden | Turkey | Spain | France | France |
| Number of patients (M/F) | 88 (3.5) | 234 (1.05) | 205 (0.55) | 142 (0.59) | 101 (1.37) | 177 (2.28) |
| Study period | 1949–1979 | 2000–2004 | 1988–1998 | 1997–1998 | 2006–2010 | 2008–2017 |
| Age ranges (means) | 2–82 (NI) | 1–88 (48.3) | 5–75 (NI) | 14–82 (52) | 5–95 (52) | 2–89 (47.4) |
| Main sources of infection | Hares | Mosquitos | Water | Hares | Hares | Hares |
| Fever | 85 | 83 | 66 | 90.8 | 67.3 | 85.0 |
| Headache | 45 | 32 | 15 | 9.9 | NA | 13.4 |
| Myalgia | 31 | NA | 6 | 25.4 | 20.8 | 25.5 |
| Arthralgia | 15 | NA | NA | 14.8 | 16.8 | 21.2 |
| Cough | 38 | 25 | NA | 24 | 5.9 | 9.2 |
| Sore throat | 15 | 3 | 58.5 | 16.9 | 15.8 | 7.0 |
| Nausea and/or vomiting | 17 | 23 | NA | 24 | 5.9 | 2.8 |
| Diarrhea | 10 | 9 | NA | 2.1 | 3.9 | 6.4 |
| Inoculation lesion | 59 | 88 | NA | 61.4 | 31.7 | 35.6 |
| Secondary dermatological lesion | 5.7 | 29.9 | 14 | 17.6 | 2.9 | 11.9 |
| Lymphadenopathy | 86 | 91.9 | 85 | 69.7 | 69.3 | 87.8 |
| Pharyngitis | 23.8 | NA | 29 | 16.2 | 19.8 | 4.2 |
| Conjunctivitis | NA | NA | 2 | NA | 2.9 | 3.5 |
| Hepatosplenomegaly | 16 | NA | 2 | NA | 2.9 | 5.6 |
| Worsening of condition | NA | NA | NA | 38.7 | 3.9 | 33.8 |
Abbreviations: M/F, male/female sex ratio; NA, no data available; Ref, reference.
aAll data are given as percentages unless otherwise specified.
Antibiotic Therapy Administred and Therapeutic Failure Rates
| Antibiotic Therapya | Total Number of Patients on Antibiotic Therapy | |
|---|---|---|
| N (%) | TF/* (%) | |
| Doxycycline, 200 mg/d | 104 (59) | 9 /91 (9.9) |
| Ciprofloxacin, 500 mg ×2/d | 21 (12) | 7/21 (33) |
| Unspecified fluoroquinolone and dosage | 11(6.2) | 4/9 (44) |
| Ofloxacin, 200 mg ×2/d | 5 (2.8) | 1/5 (20) |
| Levofloxacin, 500 mg/d | 4 (2.3) | 2/4 (50) |
| Doxycycline, 200 mg/d + IV amikacin | 2 (1.1) | 0/2 (0) |
| Ciprofloxacin, 750 mg ×2/d + IV gentamicin + doxycycline, 200 mg/d | 1 (0.56) | 0/1 (0) |
| Unspecified fluoroquinolone + IV gentamicin | 1 (0.60) | 0 (0) |
| Levofloxacin, 500 mg ×2/d + doxycycline, 200 mg/d | 1 (0.60) | 0/1 (0) |
| Ofloxacin, 400 mg ×2/d | 1 (0.60) | 0/1 (0) |
| IV amikacin | 1 (0.60) | 0/1 (0) |
| IV gentamicin | 1 (0.60) | 0/1 (0) |
| No antibiotic active on | 13 (7.3) | 0/12 (0) |
| No data | 11 (6.2) | 0/1 (0) |
Abbreviations: IV, intravenous; mg/d, milligram/day; N, number of patients; TF, therapeutic failure; ×2/d, 2 times per day.
aIf not specified, antibiotics were administred orally.
*, Number of patients for whom data are available.